Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05649228 · ClinicalTrials.gov registry record · Early Phase 1
Thermosensitivity of a Topical Palmitated Formulation of Capsaicin
A Early Phase 1 study, sponsored by Carilion Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 52
- Enrollment target
NCT05649228: Completed Early Phase 1 study, sponsored by Carilion Clinic.
NCT05649228 is a Early Phase 1 study that has completed, run by Carilion Clinic. The registered enrollment target is 52 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05649228, a Early Phase 1 study, has completed, sponsored by Carilion Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a study of the effects of capsaicin, the ingredient that makes hot peppers hot. Capsaicin is currently used in topical ointments to provide temporary relief of minor aches and joint pain associated with arthritis, simple backache, strains, and sprains. This is a pilot research study that compares the potential of two different capsaicin creams to cause irritation or burning sensation when a small amount (about the size of a quarter) is applied to each forearm of a participant. The amount of capsaicin used in the creams is the same as those found in over-the-counter capsaicin products. The test creams are experimental.
Primary Outcome
Subject assessment of any changes in the presence of a burn using a VAS scale 0 to 10 for both areas of the forearms where topical cream was applied.
Interventions
- DRUG Placebo Cream
- DRUG Capsaicin 0.1% Cream
- DRUG Capsaicin Palmitate 0.25% Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2024-01-11 |
| Phase | Early Phase 1 |
What the finished NCT05649228 record still lists
NCT05649228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo Cream is the first listed.
NCT05649228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05649228 about?
NCT05649228 is a clinical study titled "Thermosensitivity of a Topical Palmitated Formulation of Capsaicin". This is a study of the effects of capsaicin, the ingredient that makes hot peppers hot. Capsaicin is currently used in topical ointments to provide temporary relief of minor aches and joint pain associated with arthritis, simple backache, strains, and sprains. This is a pilot research study that co...
What is the current status of trial NCT05649228?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2022-12-13. Estimated completion is 2024-01-11.
What interventions are being tested in trial NCT05649228?
The interventions under investigation include: Placebo Cream (DRUG), Capsaicin 0.1% Cream (DRUG), Capsaicin Palmitate 0.25% Cream (DRUG).
Who is sponsoring clinical trial NCT05649228?
This trial is sponsored by Carilion Clinic, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05649228's enrollment target sits among peer trials
52 477th of 2000 higher than 1,516 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI